Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease
Hana You, Louise‐Laure Mariani, Graziella Mangone, et al.
Cell and Tissue Research (2018) Vol. 373, Iss. 1, pp. 111-135
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Virendra Kumar Yadav, Seshathiri Dhanasekaran, Nisha Choudhary, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 2
Control of Reactive Oxygen Species for the Prevention of Parkinson’s Disease: The Possible Application of Flavonoids
Tae Yeon Kim, Eunju Leem, Jae Man Lee, et al.
Antioxidants (2020) Vol. 9, Iss. 7, pp. 583-583
Open Access | Times Cited: 85
Effect of citronellol on oxidative stress, neuroinflammation and autophagy pathways in an in vivo model of Parkinson's disease
Richard L. Jayaraj, Sheikh Azimullah, Khatija Parekh, et al.
Heliyon (2022) Vol. 8, Iss. 11, pp. e11434-e11434
Open Access | Times Cited: 38
Effects and Mechanisms of Exercise on Brain-Derived Neurotrophic Factor (BDNF) Levels and Clinical Outcomes in People with Parkinson’s Disease: A Systematic Review and Meta-Analysis
Daan G. M. Kaagman, Erwin E. H. van Wegen, Natalie Cignetti, et al.
Brain Sciences (2024) Vol. 14, Iss. 3, pp. 194-194
Open Access | Times Cited: 10
Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia
Long Binh Vong, Yuna Sato, Pennapa Chonpathompikunlert, et al.
Acta Biomaterialia (2020) Vol. 109, pp. 220-228
Closed Access | Times Cited: 63
Puerarin suppresses MPP+/MPTP-induced oxidative stress through an Nrf2-dependent mechanism
Xiaoming Li, Jing Zhang, Xiaojie Zhang, et al.
Food and Chemical Toxicology (2020) Vol. 144, pp. 111644-111644
Closed Access | Times Cited: 49
Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in PArkiNson Disease (EXPAND) study
Anna Picca, Riccardo Calvani, Giovanni Landi, et al.
Experimental Gerontology (2019) Vol. 128, pp. 110766-110766
Closed Access | Times Cited: 48
Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
Sara Redenšek, Dušan Flisar, Maja Kojović, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 43
Neuroprotection through G-CSF: recent advances and future viewpoints
Vikrant Rahi, Sumit Jamwal, Puneet Kumar
Pharmacological Reports (2021) Vol. 73, Iss. 2, pp. 372-385
Closed Access | Times Cited: 37
Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease
Obaydah Abd Alkader Alabrahim, Hassan Mohamed El-Said Azzazy
Nanoscale Advances (2022) Vol. 4, Iss. 24, pp. 5233-5244
Open Access | Times Cited: 24
Role of Ceramides and Sphingolipids in Parkinson's Disease
Melissa Vos, Christine Klein, Andrew A. Hicks
Journal of Molecular Biology (2023) Vol. 435, Iss. 12, pp. 168000-168000
Open Access | Times Cited: 14
In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A2AReceptor Antagonist/Inverse Agonist
Yutaro Ohno, Michihiko Suzuki, Hidetsugu Asada, et al.
Molecular Pharmacology (2023) Vol. 103, Iss. 6, pp. 311-324
Closed Access | Times Cited: 12
Beyond Insulin: The Intriguing Role of GLP-1 in Parkinson's Disease
Aanchal Verma, Ahsas Goyal
European Journal of Pharmacology (2024) Vol. 982, pp. 176936-176936
Closed Access | Times Cited: 4
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
Nicola Brice, Hans H. Schiffer, Holger Monenschein, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 377, Iss. 3, pp. 407-416
Open Access | Times Cited: 25
Remote Photobiomodulation Treatment for the Clinical Signs of Parkinson's Disease: A Case Series Conducted During COVID-19
Ann Liebert, Brian Bicknell, E‐Liisa Laakso, et al.
Photobiomodulation Photomedicine and Laser Surgery (2021) Vol. 40, Iss. 2, pp. 112-122
Closed Access | Times Cited: 23
Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease
Lyudmila P. Dolgacheva, В. П. Зинченко, Н. В. Гончаров
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13043-13043
Open Access | Times Cited: 16
Significant potential of melatonin therapy in Parkinson’s disease – a meta-analysis of randomized controlled trials
Sadaf Iftikhar, Hafiz Muhammad Sameer, Zainab
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 10
Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease
Sara Redenšek, Dušan Flisar, Maja Kojović, et al.
Journal of Neuroinflammation (2019) Vol. 16, Iss. 1
Open Access | Times Cited: 26
The Importance of Drosophila melanogaster Research to UnCover Cellular Pathways Underlying Parkinson’s Disease
Melissa Vos, Christine Klein
Cells (2021) Vol. 10, Iss. 3, pp. 579-579
Open Access | Times Cited: 22
Normalization effect of dopamine replacement therapy on brain functional connectome in Parkinson's disease
Chenqing Wu, Haoting Wu, Cheng Zhou, et al.
Human Brain Mapping (2023) Vol. 44, Iss. 9, pp. 3845-3858
Open Access | Times Cited: 8
Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy
Natalia Siwecka, Kamil Saramowicz, Grzegorz Galita, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2051-2051
Open Access | Times Cited: 8
The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease
Erinaldo Ubirajara Damasceno dos Santos, Tiago Furtado Sampaio, Aléxia D Tenório dos Santos, et al.
Journal of Pharmacy and Pharmacology (2018) Vol. 71, Iss. 2, pp. 206-212
Closed Access | Times Cited: 24
Noscapine Prevents Rotenone-Induced Neurotoxicity: Involvement of Oxidative Stress, Neuroinflammation and Autophagy Pathways
Richard L. Jayaraj, Rami Beiram, Sheikh Azimullah, et al.
Molecules (2021) Vol. 26, Iss. 15, pp. 4627-4627
Open Access | Times Cited: 18
Sustained Systemic Antioxidative Effects of Intermittent Theta Burst Stimulation beyond Neurodegeneration: Implications in Therapy in 6-Hydroxydopamine Model of Parkinson’s Disease
Milica Zeljković, Jelena Stanojevic, Ivana Stevanović, et al.
Antioxidants (2024) Vol. 13, Iss. 2, pp. 218-218
Open Access | Times Cited: 2
Structural insights into the high basal activity and inverse agonism of the orphan receptor GPR6 implicated in Parkinson’s disease
Mahta Barekatain, Linda C. Johansson, Jordy Homing Lam, et al.
Science Signaling (2024) Vol. 17, Iss. 865
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top